Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

44
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
44
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

103
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
103
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

682
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
682
Angina IV: Management01:26

Angina IV: Management

40
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
40
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

36
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
36
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

975
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
975

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Financial Toxicity: Inequities and Impact on Cardiovascular Disease.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Post-PCI Physiological Testing: Phenotyping Future Failure.

JACC. Cardiovascular interventions·2026
Same author

Attempting to Define the Boundaries of Medical Futility in Contemporary Interventional Cardiology.

JACC. Cardiovascular interventions·2025
Same author

Successful Intravascular Lithotripsy Within a Covered Coronary Stent.

Journal of the Society for Cardiovascular Angiography & Interventions·2025
Same author

Diagnostic and prognostic utility of fractional flow reserve for in-stent restenosis.

Cardiovascular revascularization medicine : including molecular interventions·2025
Same author

Pocking the Ear for HFpEF?

Cardiovascular drugs and therapy·2025
Same journal

GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

Cardiovascular drugs and therapy·2026
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
See all related articles

Related Experiment Video

Updated: Oct 3, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Do We Really Need Aspirin Loading for STEMI?

Regina Ye1, Hani Jneid2, Mahboob Alam2

  • 1University of Texas at Austin, Austin, TX, USA.

Cardiovascular Drugs and Therapy
|February 16, 2022
PubMed
Summary
This summary is machine-generated.

Aspirin loading may hinder protective effects against heart attack damage. Research suggests it could reduce the benefits of treatments like statins and postconditioning, prompting a need for new clinical trials.

Keywords:
Animal modelsAspirinHumansInfarct sizePostconditioningReperfusion injurySTEMIStatins

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Related Experiment Videos

Last Updated: Oct 3, 2025

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

25.7K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Current ST-elevation myocardial infarction (STEMI) guidelines recommend immediate aspirin loading for its antiplatelet effects.
  • Reperfusion injury contributes significantly to myocardial cell death post-STEMI.
  • Many interventions effective in animal models fail in clinical trials for limiting infarct size.

Approach:

  • This review hypothesizes that aspirin loading might be responsible for the clinical failure of protective interventions.
  • Examines animal model data where aspirin administration before reperfusion attenuated protective effects of statins, ticagrelor, morphine, and postconditioning.
  • Proposes further studies in large animal models to investigate aspirin's impact on infarct-limiting strategies.

Key Points:

  • Aspirin administered before reperfusion may negate the infarct-size-limiting benefits of other therapies.
  • Data suggests aspirin loading could be the "culprit" in the failure of these interventions in clinical settings.
  • The protective effects of statins, ticagrelor, morphine, and ischemic postconditioning were observed to be attenuated when aspirin was given prior to reperfusion.

Conclusions:

  • Further research is warranted to study the effects of aspirin loading before reperfusion on infarct size limitation.
  • Suggests large animal models with extended reperfusion periods to validate the hypothesis.
  • If confirmed, clinical trials comparing aspirin loading to alternative antiplatelet strategies in STEMI patients are recommended.